LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

Search

CorMedix Inc

Avatud

SektorTervishoid

7.17 -1.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.02

Max

7.38

Põhinäitajad

By Trading Economics

Sissetulek

89M

109M

Müük

65M

104M

P/E

Sektori keskmine

3.172

108.767

Kasumimarginaal

104.112

Töötajad

64

EBITDA

37M

57M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+87% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

24. märts 2026

Turustatistika

By TradingEconomics

Turukapital

-316M

552M

Eelmine avamishind

8.68

Eelmine sulgemishind

7.17

Uudiste sentiment

By Acuity

31%

69%

87 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

CorMedix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. veebr 2026, 22:04 UTC

Tulu

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26. veebr 2026, 23:55 UTC

Market Talk

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26. veebr 2026, 23:37 UTC

Market Talk

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26. veebr 2026, 23:32 UTC

Tulu

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26. veebr 2026, 23:19 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26. veebr 2026, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26. veebr 2026, 23:12 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

26. veebr 2026, 23:12 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26. veebr 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26. veebr 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 22:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. veebr 2026, 22:43 UTC

Market Talk

RBA Hike In March Is Being Underpriced -- Market Talk

26. veebr 2026, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26. veebr 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26. veebr 2026, 22:13 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26. veebr 2026, 21:59 UTC

Tulu

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26. veebr 2026, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. veebr 2026, 21:49 UTC

Tulu

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26. veebr 2026, 21:45 UTC

Tulu

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26. veebr 2026, 21:44 UTC

Tulu

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26. veebr 2026, 21:44 UTC

Tulu

Coles Expects Market to Remain Highly Competitive

26. veebr 2026, 21:44 UTC

Tulu

Coles Says Supermarket Customers Remain Value Oriented

26. veebr 2026, 21:43 UTC

Tulu

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26. veebr 2026, 21:43 UTC

Tulu

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26. veebr 2026, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26. veebr 2026, 21:41 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

CorMedix Inc Prognoos

Hinnasiht

By TipRanks

87% tõus

12 kuu keskmine prognoos

Keskmine 13.67 USD  87%

Kõrge 15 USD

Madal 13 USD

Põhineb 4 Wall Streeti analüütiku instrumendi CorMedix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

9.2 / N/AToetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

87 / 352 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
help-icon Live chat